InMed Pharmaceuticals Inc.
INM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.01 | 0.01 | -0.01 |
| FCF Yield | -18,562.70% | -27.33% | -73.15% | -74.71% |
| EV / EBITDA | 5,805.30 | 1.57 | 0.78 | -0.42 |
| Quality | ||||
| ROIC | -0.01% | -17.19% | -26.88% | -30.94% |
| Gross Margin | 35.99% | 44.20% | 13.92% | 41.46% |
| Cash Conversion Ratio | 0.93 | 0.99 | 0.78 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.19% | 1.53% | 23.26% | 36.41% |
| Free Cash Flow Growth | 9.61% | -7.17% | 33.68% | -36.97% |
| Safety | ||||
| Net Debt / EBITDA | 5,805.30 | 4.24 | 1.92 | 1.18 |
| Interest Coverage | 0.00 | -121.87 | 0.00 | -6.28 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 1.03 | 1.33 | 0.59 |
| Cash Conversion Cycle | 139,355.29 | 77.19 | 47.30 | 94.38 |